|
SocialPicks Sentiment:
N/A
** not enough data to be rated
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Look for Laggards after Latest Rally
CPD
|
|
|
<> 
With the S&P 500 SPDR (SPY) trading to the upside by more than 10% in the last five days on the prospects for a short-term $15B rescue package for U.S. auto makers to prevent rising unemployment rates from skyrocketing into double digits, Caraco Pharma (CPD) and Altria Group (MO) represent two laggards from defensive industry groups.
The accompanying one-month chart [click to enlarge] illustrates a highly correlated sell-off in Caraco and another small generic drug company, Hi-Tech Pharmacal (HITK), with H...
|
Stock Ideas from ETF Innovators New Indexes
CPD
|
|
|
<> Below is a list of 14 stock opportunities from various ETF Innovators [ETFI] indexes, which includes a database of over 1,000 companies. The companies are chosen across a full spectrum of market cap and risk level from a variety of industry groups.
From the ETFI Highly Defensive PerformIdex , I believe Altria Group (MO) and Pfizer (PFE) are defensive dividend, value buys at current levels as each company currently pays a dividend of $1.28 per share annually – resulting in historically high dividend yields for bot<>< />< /><><><>< />< /><><><>< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><>< />< /><><><><>< />< />< />< />< />< />< />< />...
|
A Coiled Spring: Near-Term Catalysts & Oversold Stocks
CPD
|
|
|
<> AMAG Pharma (AMAG) more than doubled on word that the FDA accepted its complete response for a NDA of iron-deficiency anemia drug ferumoxytol in patients with chronic kidney disease and will issue a final ruling before year-end. The news is a major relief for AMAG as no new clinical trials were required and the quick decision deadline before year-end is encouraging for the approval prospects of ferumoxytol.
A trio of companies expect FDA decisions for abuse-resistant pain drugs before year-end, including Pain The...
|
Generic Cardio Drugs Equal Brands - JAMA
CPD
|
|
|
<> 
A meta-analysis review of clinical studies published in peer-reviewed journals was featured today in The Journal of the American Medical Association [JAMA] and concluded that cost-saving generics used to treat a variety of cardiovascular conditions produced equivalent clinical outcomes to higher cost brand name drugs. Despite this clinical evidence, the review notes that a majority (53%) of the 43 editorials analyzed had a negative opinion on generic substitution.
While there are currently no ETFs on the market w...
|
Caraco Pharma: Defensive Growth at a Value Price
CPD
|
|
|
<> Caraco Pharma (CPD) offers a compelling value at its current price of $3.30 per share and I bought some shares today, as the stock has lost an astounding two-thirds of its market value in just the past month and over three-quarters of value in the past year.
1.) Defensive: Healthcare Sector, Generic Drug Industry
2.) Growth: Net income of $17.9M for the first six months of FY09 (up 36% from the year-ago period) on $230.5M in revenue for the same time period (up 200% from a year ago) – largely due to a distributi<>< />< /><>< />< />< />< />< />< />...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Caraco Pharmaceutical Labortories Ltd
- Answers.com
